Skip to main content
Premium Trial:

Request an Annual Quote

Illumina's Q3 Revenue Surges 82 Percent on Strong Product Sales, Though Profit Slides

NEW YORK (GenomeWeb News) — Illumina yesterday said third-quarter revenues bolted 82 percent and R&D spending rose 160 percent, though profits fell 10 percent.
Total receipts for the three months ended Sept. 30 increased to $97.5 million from $53.5 million year over year.
Product revenues leapt to $90 million from $46.9 million, while service and other revenue rose to $7.4 million from $6.4 million year over year.
R&D spending increased to $19.8 million from $7.7 million in the year-ago period, including around $13.2 million in non-cash stock compensation expenses.
Profit for the quarter declined to $14.5 million from $16.2 million.
Illumina said it had around $352.8 million in cash, equivalents, and short-term investments as of Sept. 30.
The company raised its expected full-year 2007 revenue to between $354 million and $358 million, which is $16 million higher than projections it made in July, or around 17 percent more than it projected at the beginning of the year.
Illumina expects fourth-quarter revenue to be between $100 million and $104 million, or as much as 69 percent over the same period last year.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.